StockWatch
·

Ugro Capital Ltd Q2 FY27 Results

UGROCAPQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue461.4710.6%1.3%
Total Income495.519.2%7.4%
Expenditure445.579.9%11.4%
PBT49.942.6%18.3%
Net Profit37.3738.5%13.7%
OPM62.90%1.78pp0.34pp
NPM7.54%5.83pp1.85pp
EPS2.4538.3%35.4%
View full financials

Core NBFC profitability deteriorated — net profit fell 13.7% YoY on flat revenue (+1.3%) with NPM slipping from 9.4% to 7.5%, a below-par quarter for the sector.

UGRO CAPITAL · Q2 FY27 · THE VERDICT

Disbursements surge 77%, profit falls 44%: the pivot that spooked the market

Management executed a deliberate portfolio pivot from volume-heavy defocused lending to high-yield focused businesses. The strategy is working—but the reported numbers tell the opposite story, and the market has voted with its feet.

13 Nov 2026 · 6 min read
Reported PAT

₹37.4 Cr

-13.7% YoY, -44.9% QoQ

PBT (underlying)

₹68.3 Cr

+12% YoY

Mix shift vector

Defocused → Focused

32% baseline → 53% focus

Disbursements

₹3,159 Cr

+77% YoY momentum

The quarter in one tension

Ugro Capital reported Q2 revenue of ₹461.5 Cr, essentially flat (+1.3% YoY), and PAT of ₹37.4 Cr, down 13.7% YoY and a stunning 44.9% QoQ. Yet the company disbursed ₹3,159 Cr in the quarter—77% more than a year ago—and the two growth businesses that management has been betting on (Emerging Market LAP and GROx embedded merchant finance) are firing on all cylinders. The profit miss was not a failure of origination or cost control. It was a deliberate trade: management shifted the portfolio from high-volume, low-yield defocused lending to high-yield, lower-volume focused lending. Revenue per rupee of disbursement fell as a result. That shift is rational and strategic. But the reported P&L is now noisy with one-time merger accounting adjustments (the Profectus integration is pending NCLT final approval on Nov 20), and the market has lost patience.

Where the profit went

Reported PAT of ₹37.4 Cr sits below PBT of ₹68.3 Cr (+12% YoY) due to tax timing and merger-related adjustments. More important: the company's interest income rose 20% YoY to ₹385.5 Cr (portfolio yield now 18.7%, up 108 basis points), but other income was held flat by ₹51.8 Cr in co-lending reversals as management shifted income recognition to behavioral tenure (a conservative accounting move). Those reversals are temporary; as the defocused book winds down, reversal headwinds will abate. But in Q2, they masked the strength in core lending income.

Q2 FY27 growth rates (%)
-24.5812.9150.3987.8877Disbursements20Interest income1.3Revenue-13.7PAT
The divergence: volume and yield growing, but revenue and profit lagging due to portfolio mix shift (intentional yield-over-volume trade) and merger accounting.

What changed on this call

Portfolio rebalance accelerated. In nine months, management shifted the focus-business mix from 32% of AUM (baseline, Sep 2025) to 53% as of Q2. Emerging Market LAP grew 42% YoY to ₹4,268 Cr; GROx grew 22% QoQ to ₹3,661 Cr. The defocused book (legacy, high-volume, low-yield co-lending portfolio) is winding down as planned, with repayments and foreclosures running ahead of schedule. That is why total AUM grew only 23% YoY despite the two focus businesses shooting forward—the defocused rundown offsets.

Disbursement engine humming. ₹1,000+ Cr in disbursements every month in Q2 (July, Aug, Sept) is the highest monthly run-rate in the company's history. LAP is disbursing via 317 branches across 13 states with 1.8k+ sales staff; GROx is embedded in payment-app ecosystems (PhonePe, Paytm, BharatPay) and is touching 4.1 lakh active merchants. Neither strategy is a hope—it is live.

Operating cost stayed disciplined. Q2 opex of ₹127.2 Cr is down 7% YoY and down 37% from Q4 FY26 (₹203 Cr, which was inflated by merger costs). The FY27 annual guidance of ₹490 Cr is tracking—roughly ₹122.5 Cr per quarter. That is opex leverage as AUM grows.

Profectus merger pending final approval. The NCLT is scheduled to hear the scheme on Nov 20. Once approved, the merger closes, and the reported-number volatility from goodwill remeasurement (₹308 Cr), acquisition costs (₹266 Cr), and excess-interest-spread revaluation will stabilize. Until then, expect continued one-time adjustments. Management has disclosed a pro forma net worth of ₹2,454 Cr vs. reported ₹195 Cr per share, showing the magnitude of the accounting bridge.

Management claims vs. what holds up

Disbursements strong at ₹3,159 Cr (77% YoY)

Metric

₹3,159 Cr, +77% YoY confirmed

Verdict

Supported

Operating cost down 7% YoY to ₹127.2 Cr; on track for ₹490 Cr FY27

Metric

₹127.2 Cr confirmed; ₹490 Cr annual tracking ~₹122 Cr/qtr

Verdict

Supported

Focus businesses (LAP+GROx) now 53% of AUM, targeting 87% by FY29

Metric

LAP ₹4,268 Cr (+42% YoY), GROx ₹3,661 Cr (+22% QoQ); 53% composition confirmed

Verdict

Supported

PAT momentum driving margin expansion ahead

Metric

Delivered PAT ₹37.4 Cr, down 13.7% YoY; PBT up 12% but PAT compressed by tax and merger adjustments

Verdict

Contradicted—near-term margin under pressure due to mix shift and merger accounting

How the street sees it

The market has moved decisively against UGRO. FII ownership has cratered from 29.32% in Q1 FY26 to 5.45% in Q1 FY27—a withdrawal of 2,387 basis points. The stock trades at ₹68.02, down 78% from its all-time high of ₹312.7, and sits below all major moving averages (SMA20 ₹73.8, SMA50 ₹79.17, SMA200 ₹97.86). Book value (pro forma) is ₹2,454 Cr; market cap is ₹1,130 Cr—the stock is priced at 0.4x adjusted book. RSI stands at 30.3, technically oversold but not reversing. Volume is normal, not panic capitulation.

What spooked the FII: (1) the reported profit miss, which hit hardest on a QoQ basis (–44.9%), compounding the perception that the pivot had backfired; (2) confusion around merger accounting and the opacity of pro forma vs. reported numbers; (3) GROx's youth as a business—only 25 months old, and external shocks (Middle East tensions in Aug 2025) briefly spiked merchant defaults, reminding the market that short-tenor merchant lending has tail risk; (4) the execution bet itself—management's Feb 2026 pivot was aggressive, and the near-term reported-number deterioration tested patience before the strategy could deliver upside. The market interpreted the pivot as a sign of distress, not opportunity.

Ranked risks for a holder

Risks ordered by impact to equity value

Merger accounting complexity creates reported-number opacity through FY28

High

₹120+ Cr in one-time adjustments (goodwill, reversals, fair-value remeasurement) will create periodic earnings surprises until the Profectus integration fully closes. Investors discount opaque earnings; the 0.4x book valuation reflects this.

GROx merchant-lending credit risk if macro downturn hits small retailers

High

GROx is only 25 months old and has seen two full cycles. Portfolio yield is 26%, but unsecured merchant lending can see rapid loss severity if economic shock hits. Daily monitoring and 70–75% PCR are mitigants, but a 1% swing in credit cost could swing PAT ₹35+ Cr.

Portfolio concentration in focus businesses (53% and targeting 87% by FY29)

Medium

Both LAP and GROx target small-business lending. Sector-wide shock (credit freeze on SME lending, rate shock, or policy change) could spike credit losses portfolio-wide. Defocused book rundown limits diversification for 2–3 years.

Interest-rate sensitivity; 50–50 fixed-floating mix with 1-year MCLR reset

Medium

Recent RBI hikes will flow through in 12 months; management expects 15–20 basis points headwind to NIM. Cost of borrowing already up 5 basis points QoQ. If lending rates do not reset in lockstep, net interest margin compresses.

Profectus NCLT approval delay or rejection

Medium

Final sanction hearing scheduled Nov 20. Delay would extend reported-number volatility and leave balance-sheet integration incomplete. Rejection would force recapitalization and re-strategy; highly unlikely but not zero risk.

The bull-bear ledger
  • Disbursements momentum: ₹1,000+ Cr monthly, highest in company history

  • Focus-business CAGR targets being beaten (LAP 42% YoY vs. 20–30% target)

  • Operating-cost discipline: 7% YoY decline, on track for FY27 guidance

  • Interest income growth 20% YoY; portfolio yield expanding (18.7%, up 108 bps)

  • Reported PAT down 44.9% QoQ—a severe miss on near-term basis

  • Revenue growth only 1.3% YoY despite 77% disbursement growth—mix-shift headwind is real

  • GROx only 25 months old; credit risk unproven through full cycle

  • Merger accounting opacity creates reported-number risk through FY28

  • FII exodus (–2,387 bps in 12 months) signals conviction bearishness

  • Valuation at 0.4x pro forma book is deep discount; suggests market pricing in scenario risk

What to watch next—the three tests of execution
  • 1 · Profectus NCLT final sanction (Nov 20, 2026)

    Merger approval will unlock reported-number clarity and end goodwill/fair-value remeasurement volatility. Market re-rates equity heavily on visibility; if Nov 20 hearing clears, expect re-rating rally in subsequent weeks.

  • 2 · Q3 FY27 organic profit recovery

    Management committed "every quarter should be better." Q3 will be the first real test post-Profectus. If organic profit (ex reversals, merger adjustments) grows QoQ and inflects upward, the bear case weakens materially. If PAT remains flat or declines, execution doubt hardens.

  • 3 · Credit-rating upgrade by end CY26

    Agencies are engaged (plan set in Feb 2026). Rating upgrade would lower UGRO's borrowing cost, expanding NIM. Upgrade also signals third-party validation of the pivot. If upgrade clears, cost-of-borrowing pressure eases and ROA target credibility rises.

  • 4 · Focus-business CAGR tracking through FY29

    LAP target 20–30% annual CAGR (Q2 actual 42% YoY—well ahead). GROx target 35–40% (Q2 actual 22% QoQ—tracking on annualized basis; new business at 25 months). Both are beating current guidance. Monitor whether momentum is sustainable through macro cycles. This is the ultimate credibility test for the FY29 ROA 3.0–3.5% pathway.

Ugro Capital is in the middle of a portfolio pivot that will take 18–24 months to fully play out. The strategy is sound—high-yield, lower-volatility lending beats the old co-lend trap. Execution metrics (disbursements, focus-book growth, opex discipline) are on track. But reported profit has deteriorated sharply, merger accounting is clouding the picture, and the market has voted with its feet—FII down 2,387 basis points, stock down 78%, valuation at 0.4x book.

For a holder or prospective buyer, the critical question is not whether the strategy is good—it is—but whether management can deliver organic profit growth while integration headwinds ease. Profectus NCLT approval on Nov 20 is the first gate. Q3 organic PAT inflection is the second. If both clear, the 0.4x valuation will look generous in hindsight. If either wobbles, the market's pessimism is justified.

The single number to track from here is organic PAT growth on a QoQ basis (excluding merger adjustments and reversals). That will tell you whether the pivot is working or whether reported numbers are about to disappoint for a third or fourth quarter. Until that turns positive, the near-term tape stays under pressure, regardless of the long-term thesis.

Informational and educational content only. Not investment advice.